The rational approach to selection of anticoagulation for stroke prevention in patients with atrial fibrillation of non-valvular etiology
Abstract
The question of how to use most eff ectively and safely drugs from the group of oral anticoagulants for prevention of thromboembolic complications (TEC) in patients with atrial fi brillation (AF) non-valvular etiology is analyzed in this paper.
About the Authors
D. A. Napalkov
Clinical Centre «Arrhythmology»; I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Dmitry Aleksandrovich Napalkov,, MD, deputy director in research and innovation; head of the Research Department of arrhythmology of the Research Centre, professor of the chair of the faculty therapy № 1
6 B. Pirigovskaya str., Moscow, 119435
8 (499) 248–62–22
A. A. Sokolova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
physician of the Clinical Centre
References
1. Guidelines for the management of atrial fi brillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery / A.J. Camm, P. Kirchhof, G.Y. Lip et al. // Eur Heart J 2010. Vol. 31. P. 2369–2429.
2. Selecting patients with atrial fi brillation for anticoagulation. Stroke risk stratifi cation in patients taking aspirin / B.F. Gage, C. van Walraven, L. Pearce et al. // Circulation. 2004. Vol. 110. P. 2287–2292.
3. Guidelines for the management of atrial fi brillation: Focused update of the ESC Guidelines An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association/ A. John Camm, Gregory Y.H. Lip, Raff aele De Caterina // Eur Heart J (2012) Vol. 33, P.2719–2747
4. Aspirin in stroke prevention in nonvalvular atrial fi brillation and stable vascular disease. An era of new anticoagulants / M.K. Turagam, P. Velagapudi, M.A. Leal, A.G. Kocheril // Expert Rev Cardiovasc Ther 2012. Vol. 10. P. 433–439.
5. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fi brillation // Ann Intern Med. 2007. Vol. 146. P. 857–867.
6. New antithrombotic agents insights from clinical trials / J. S. Paikin, J. Eikelboom, J.A. Cairns, J. Hirsh // Nat Rev Cardiol. 2010. Vol. 7. P. 498–509.29
7. Dabigatran versus warfarin in patients with atrial fi brillation / S.J. Connolly, M. D. Ezekowitz, S. Yusuf et al. // N Eng J Med 2009. Vol. 361. P. 1139–1151.
8. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation / M.R. Patel, K. W. Mahaff ey, J. Garg et al. // N. Eng. J. Med. 2011. Vol. 365. P. 883–891.
9. Net clinical benefi t of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a «real world» atrial fi brillation population: a modeling analysis based on a nationwide cohort study / A. Banerjee, D.A. Lane, C. Torp-Pedersen et al. // Thromb Haemost 2012. Vol. 107. P. 584–589.
10. Annex 1 Summary of Product Characteristics Rivaroxaban. http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_30Sept2008.pdf Arbit E. Goldberg M
11. Kubitza D., Becka M., Mueck W. et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban — an oral direct Factor Xa inhibitor. Blood 2006;108:Abstract 905.
12. Kubitza D., Becka M., Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59- 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412—21.
13. Eikelboom J.W., O'Donnell M., Yusuf S. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fi brillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159, 348–353 (2010).
14. Lip G.Y.H., Frison L. and Grind M. on behalf of the SPORTIF Investigators. Eff ects of hypertension on anticoagulated patients with atrial fi brillation. Eur Heart J 2007; 28: 752-759.
15. Mammen E.F. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6: 1247-1257.
16. Landefeld C.S., Cook E.F., Flatley M. et al: Identifi cation and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-713.
17. Brigden M.L., Kay C., Le A. et al. Audit of the frequency and clinical response to excessive oral anticoagulation in an outpatient population. Am J Hematol 1998; 59: 22-27.
18. Graff J., Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabagatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013; 52 (4): 243-54.
19. Soliman E.Z. et al. Chronic kidney disease and prevalent atrial fi brillation: the Chronic Renal Insuffi ciency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107.
20. Fox K.A. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fi brillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
Review
Views:
263
Email this article 